🧬 #ASH26 #Weekend_Review #TP53-mt MN
Several evolving themes: allelic state & LOH, disease heterogeneity, transplant, immune biology &emerging therapeutic vulnerabilities.
Also excited to share our work on #PPM1D, #DDX41, and a better prognostic TP53 subset from the #COMMAND_consortium.
Several evolving themes: allelic state & LOH, disease heterogeneity, transplant, immune biology &emerging therapeutic vulnerabilities.
Also excited to share our work on #PPM1D, #DDX41, and a better prognostic TP53 subset from the #COMMAND_consortium.
November 15, 2026 at 5:19 AM
🧬 #ASH26 #Weekend_Review #TP53-mt MN
Several evolving themes: allelic state & LOH, disease heterogeneity, transplant, immune biology &emerging therapeutic vulnerabilities.
Also excited to share our work on #PPM1D, #DDX41, and a better prognostic TP53 subset from the #COMMAND_consortium.
Several evolving themes: allelic state & LOH, disease heterogeneity, transplant, immune biology &emerging therapeutic vulnerabilities.
Also excited to share our work on #PPM1D, #DDX41, and a better prognostic TP53 subset from the #COMMAND_consortium.
#weekend_review Venetoclax in ALL: an evolving story
VEN combinations are showing encouraging activity across frontline Ph− ALL and R/R B- and T-ALL
BH3 profiling offers a functional way to interrogate these dependencies—but remains investigational in ALL
Visual summary 👇
#ALL #Leukemia
VEN combinations are showing encouraging activity across frontline Ph− ALL and R/R B- and T-ALL
BH3 profiling offers a functional way to interrogate these dependencies—but remains investigational in ALL
Visual summary 👇
#ALL #Leukemia
November 1, 2026 at 3:49 PM
#weekend_review Venetoclax in ALL: an evolving story
VEN combinations are showing encouraging activity across frontline Ph− ALL and R/R B- and T-ALL
BH3 profiling offers a functional way to interrogate these dependencies—but remains investigational in ALL
Visual summary 👇
#ALL #Leukemia
VEN combinations are showing encouraging activity across frontline Ph− ALL and R/R B- and T-ALL
BH3 profiling offers a functional way to interrogate these dependencies—but remains investigational in ALL
Visual summary 👇
#ALL #Leukemia
#weekend_review #mdssm HIGHER-RISK #MDS: A DECADE OF CLINICAL TRIALS
The last decade in HR-MDS has taught us a humbling lesson
Promising biology ≠ successful phase III trial.
Higher response rate ≠ longer survival.
why so many failed, and where we go next. 👇
The last decade in HR-MDS has taught us a humbling lesson
Promising biology ≠ successful phase III trial.
Higher response rate ≠ longer survival.
why so many failed, and where we go next. 👇
September 20, 2026 at 11:51 PM
#weekend_review #mdssm HIGHER-RISK #MDS: A DECADE OF CLINICAL TRIALS
The last decade in HR-MDS has taught us a humbling lesson
Promising biology ≠ successful phase III trial.
Higher response rate ≠ longer survival.
why so many failed, and where we go next. 👇
The last decade in HR-MDS has taught us a humbling lesson
Promising biology ≠ successful phase III trial.
Higher response rate ≠ longer survival.
why so many failed, and where we go next. 👇
